- Home
- LTRN vs LGVN Comparison
LTRN vs LGVN Comparison
Compare LTRN & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRN
- LGVN
- Stock Information
- Founded
- LTRN 2013
- LGVN 2014
- Country
- LTRN United States
- LGVN United States
- Employees
- LTRN N/A
- LGVN N/A
- Industry
- LTRN Biotechnology: Pharmaceutical Preparations
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- LTRN Health Care
- LGVN Health Care
- Exchange
- LTRN Nasdaq
- LGVN Nasdaq
- Market Cap
- LTRN 35.4M
- LGVN 28.4M
- IPO Year
- LTRN 2020
- LGVN 2021
- Fundamental
- Price
- LTRN $3.11
- LGVN $1.76
- Analyst Decision
- LTRN Hold
- LGVN Strong Buy
- Analyst Count
- LTRN 1
- LGVN 3
- Target Price
- LTRN N/A
- LGVN $8.67
- AVG Volume (30 Days)
- LTRN 77.7K
- LGVN 324.6K
- Earning Date
- LTRN 11-07-2024
- LGVN 11-12-2024
- Dividend Yield
- LTRN N/A
- LGVN N/A
- EPS Growth
- LTRN N/A
- LGVN N/A
- EPS
- LTRN N/A
- LGVN N/A
- Revenue
- LTRN N/A
- LGVN $1,852,000.00
- Revenue This Year
- LTRN N/A
- LGVN $208.32
- Revenue Next Year
- LTRN N/A
- LGVN $43.96
- P/E Ratio
- LTRN N/A
- LGVN N/A
- Revenue Growth
- LTRN N/A
- LGVN 141.46
- 52 Week Low
- LTRN $2.79
- LGVN $0.77
- 52 Week High
- LTRN $11.99
- LGVN $14.80
- Technical
- Relative Strength Index (RSI)
- LTRN 41.22
- LGVN 36.55
- Support Level
- LTRN $3.28
- LGVN $1.80
- Resistance Level
- LTRN $3.60
- LGVN $1.72
- Average True Range (ATR)
- LTRN 0.43
- LGVN 0.12
- MACD
- LTRN -0.06
- LGVN -0.03
- Stochastic Oscillator
- LTRN 0.00
- LGVN 16.61
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.